Sugi Predict

Sugi Predict / Compounds / SCHEMBL4460485

SCHEMBL4460485

SCHEMBL4460485

Nc1ccc(Oc2ccnc(N)c2[N+](=O)[O-])c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ HSPB1 P04792 5/20 0.40
▸ LMNA P02545 1/20 0.38
▸ AXL P30530 1/20 0.38
▸ MET P08581 4/20 0.37
▸ RET P07949 1/20 0.37
▸ KIT P10721 1/20 0.37
▸ PDGFRA P16234 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30785616 1.00 MAPT (0.47) MAPTSMN1; SMN2HSPB1LMNAAXL
SCHEMBL30785611 1.00 MAPT (0.47) MAPTSMN1; SMN2HSPB1LMNAAXL
SCHEMBL4465460 0.85 MAPT (0.45) MAPTSMN1; SMN2HSPB1LMNAALDH1A1
SCHEMBL1792475 0.84 MAPT (0.44) MAPTSMN1; SMN2HSPB1LMNAALDH1A1
SCHEMBL4465527 0.84 SMN1; SMN2 (0.48) MAPTSMN1; SMN2LMNAALDH1A1TP53
SCHEMBL4458381 0.84 PDE7A (0.48) MAPTSMN1; SMN2LMNAALDH1A1TP53
SCHEMBL1792698 0.83 MEN1 (0.45) MAPTSMN1; SMN2LMNAALDH1A1TP53
SCHEMBL28529335 0.82 MAPT (0.41) MAPTSMN1; SMN2HSPB1LMNAMET
SCHEMBL1794794 0.82 LMNA (0.55) MAPTSMN1; SMN2LMNAALDH1A1TP53
SCHEMBL2928469 0.81 MET (0.49) AXLMETRETKITPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240316017-A1 NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR LG CHEM, LTD. (KR) 2024-09-26 — — US disclosed
EP-4349826-A1 NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR LG Chem, Ltd. (KR) 2024-04-10 — — EP disclosed
CN-117412958-A Novel pyridine derivative compounds as RON inhibitors 株式会社LG化学 2024-01-16 — — CN disclosed
WO-2022270977-A1 NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR 주식회사 엘지화학 2022-12-29 — — WO disclosed
EP-1812433-B1 IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS CANCER REC TECH LTD (GB) 2015-07-22 — — EP disclosed
EP-1812433-B1 IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS CANCER REC TECH LTD (GB) 2015-07-22 — — EP disclosed
CN-101084217-B Imidazo [4,5-B] pyridin-2-ones and oxazolido [4,5-B] pyridin-2-ones and analogues thereof as therapeutic compounds CANCER REC TECH LTD 2010-10-13 — — CN disclosed
US-7625922-B2 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-01 — — US disclosed
US-7625922-B2 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-01 — — US disclosed
US-7625922-B2 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-01 — — US disclosed
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-13 — — US disclosed
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-13 — — US disclosed
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-13 — — US disclosed
CN-101084217-A Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds CANCER REC TECH LTD (GB) 2007-12-05 — — CN disclosed
EP-1812433-A1 IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS Cancer Research Technology Limited (GB) 2007-08-01 — — EP disclosed
WO-2006043090-A1 IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316017-A1 NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR RET, ROS1, MST1R MAPT 4155/4885SMN1; SMN2 4287/4885HSPB1 3654/4885
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds NR2E1, NR0B1, BRAF MAPT 4312/4885SMN1; SMN2 1298/4885HSPB1 771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.